Exscientia PLC (EXAI) - Revenue and Sales Volume

Exscientia plc (EXAI) is developing an AI ecosystem for precision drug design, deeply integrating its software into the processes of pharmaceutical behemoths. The company's sales dynamics clearly demonstrate market demand, while 0.02 reflects the latest metric value. The molecular linkage database ensures long-term royalties, and management is successfully consolidating technological platforms following acquisitions while maintaining the trust of key counterparties.

Exscientia Inc. (EXAI) - Company Revenue from 07/04/2022 to 11/30/2024

Comprehensive metric breakdowns and analytics for Exscientia PLC (EXAI)

- market value and analyst target forecast:

Market Chart Exscientia Inc.|EXAI - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Exscientia plc|EXAI - Real Price to Acquire Entire Company

- company book value details:

Accounting Value of a Share Exscientia|EXAI - Company Book Value|Market Capitalization to Net Assets exscientia.ai|EXAI - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples indicators:

EXAI - Net Profit|Company Profit Forecast Exscientia plc|EXAI - P/E Multiple|Forward P/E Multiple Exscientia Inc.|EXAI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Exscientia plc|EXAI - Operating profit EBITDA|Net earnings per one share for the last twelve months Exscientia|EXAI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months exscientia.ai|EXAI - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Exscientia plc

- sales volume and revenue indicators:

EXAI - Revenue and Sales Volume|Company Future Sales Volume Exscientia Inc.|EXAI - P/S Multiple|Market Cap to Expected Sales Ratio Exscientia plc

Summary company analysis:EXAI (exscientia.ai)

To minimize investment risks, it is necessary to track actual revenue, which confirms the execution of business plans and the probability of capital drawdown. The current value of 0.02 in the volume of Exscientia plc (EXAI) realized products reflects the monetization efficiency of its AI platform, where the speed of molecule design directly converts into revenue from strategic partnerships with global pharmaceutical behemoths.

Competing companies